Insmed reported $10.18M in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acelrx Pharmaceuticals ACRX:US $ 0.44M 0.6M
Alexion Pharmaceuticals ALXN:US $ 125.4M 26.8M
Alimera Sciences ALIM:US $ 1.69M 0.12M
Biomarin Pharmaceutical BMRN:US $ 103.54M 23.52M
Dynavax Technologies DVAX:US $ 60.09M 45.24M
Flexion Therapeutics FLXN:US $ 3.73M 1.25M
Gilead Sciences GILD:US $ 1223M 167M
Heron Therapeutics HRTX:US $ 11.35M 3.17M
Insmed INSM:US $ 10.18M 654K
Novartis NVS:US $ 3848M 94M
Regeneron Pharmaceuticals REGN:US $ 453.2M 240.5M
Sarepta Therapeutics SRPT:US $ 23.44M 3.93M
Seattle Genetics SGEN:US $ 82.65M 4.56M
Ultragenyx Pharmaceutical RARE:US $ 4.18M 1.04M
Vertex Pharmaceuticals VRTX:US $ 236.51M 8.54M